TY - JOUR
T1 - In vitro activity of arbekacin against multidrug-resistant gram-negative bacilli
AU - Albano, Mariana
AU - Fleischmann, Wim Alexander
AU - Greenwood-Quaintance, Kerryl E.
AU - Patel, Robin
N1 - Funding Information:
RP reports grants from CD Diagnostics, Merck, Hutchison Biofilm Medical Solutions, Accelerate Diagnostics, Contrafect, TenNor Therapeutics Limited, and Shionogi. RP is a consultant to Curetis, Specific Technologies, Next Gen Diagnostics, PathoQuest, Selux Dx, and Qvella; monies are paid to Mayo Clinic. RP is a consultant to Netflix. In addition, RP has a patent on Bordetella pertussis/B. parapertussis PCR issued, a patent on a device/method for sonication with royalties paid by Samsung to Mayo Clinic, and a patent on an antibiofilm substance issued. RP receives travel reimbursement from ASM and IDSA, an editor's stipend from IDSA, and honoraria from the NBME, Up-to-Date, and the Infectious Diseases Board Review Course. WAF is the chief executive officer and a shareholder at SelfCare UG (Haftungsbeschränkt), registered in Germany as HRB 760532.
Funding Information:
RP reports grants from CD Diagnostics , Merck , Hutchison Biofilm Medical Solutions , Accelerate Diagnostics , Contrafect , TenNor Therapeutics Limited , and Shionogi . RP is a consultant to Curetis, Specific Technologies, Next Gen Diagnostics, PathoQuest, Selux Dx, and Qvella; monies are paid to Mayo Clinic. RP is a consultant to Netflix. In addition, RP has a patent on Bordetella pertussis/B. parapertussis PCR issued, a patent on a device/method for sonication with royalties paid by Samsung to Mayo Clinic, and a patent on an antibiofilm substance issued. RP receives travel reimbursement from ASM and IDSA , an editor's stipend from IDSA , and honoraria from the NBME , Up-to-Date, and the Infectious Diseases Board Review Course. WAF is the chief executive officer and a shareholder at SelfCare UG (Haftungsbeschränkt), registered in Germany as HRB 760532.
Publisher Copyright:
© 2020
PY - 2021/12
Y1 - 2021/12
N2 - Background: Arbekacin is a broad-spectrum aminoglycoside with activity against some Gram-positive and Gram-negative bacteria. Methods: Arbekacin minimum inhibitory concentration (MIC) values were determined for 296 drug-resistant Gram-negative bacilli, and compared to previously determined plazomicin, amikacin, gentamicin, and tobramycin MIC values. Results: The MIC values required to inhibit 50% and 90% of isolates (MIC50 and MIC90, respectively) were 16 and >128 μg/ml, respectively. Conclusions: Arbekacin showed similar MIC50 values to amikacin and gentamicin, a lower MIC50 value than tobramycin, and a higher MIC50 value than plazomicin.
AB - Background: Arbekacin is a broad-spectrum aminoglycoside with activity against some Gram-positive and Gram-negative bacteria. Methods: Arbekacin minimum inhibitory concentration (MIC) values were determined for 296 drug-resistant Gram-negative bacilli, and compared to previously determined plazomicin, amikacin, gentamicin, and tobramycin MIC values. Results: The MIC values required to inhibit 50% and 90% of isolates (MIC50 and MIC90, respectively) were 16 and >128 μg/ml, respectively. Conclusions: Arbekacin showed similar MIC50 values to amikacin and gentamicin, a lower MIC50 value than tobramycin, and a higher MIC50 value than plazomicin.
KW - Arbekacin
KW - Enterobacterales
KW - Multidrug-resistant gram-negative bacilli
UR - http://www.scopus.com/inward/record.url?scp=85091122150&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85091122150&partnerID=8YFLogxK
U2 - 10.1016/j.jmii.2020.08.018
DO - 10.1016/j.jmii.2020.08.018
M3 - Article
C2 - 32962921
AN - SCOPUS:85091122150
SN - 1684-1182
VL - 54
SP - 1118
EP - 1121
JO - Journal of Microbiology, Immunology and Infection
JF - Journal of Microbiology, Immunology and Infection
IS - 6
ER -